Objective-Hypoglycemia is associated with increased mortality. The reasons for this remain unclear, and the effects of low glucose exposure on vascular endothelial function remain largely unknown. We endeavored to determine the effects of low glucose on endothelial cells and intact human arterioles. Methods and Results-We exposed human umbilical vein endothelial cells to low glucose conditions in a clinically relevant range (40 -70 mg/dL) and found rapid and marked reductions in nitric oxide (NO) bioavailability (PϽ0.001). This was associated with concomitantly increased mitochondrial superoxide production (PϽ0.001) and NO-dependent mitochondrial hyperpolarization (PϽ0.001). Reduced NO bioavailability was rapid and attributable to reduced endothelial nitric oxide synthase activity and destruction of NO. Low glucose rapidly activated AMP kinase, but physiological activation failed to restore NO bioavailability. Pharmacological AMP kinase activation led to phosphorylation of endothelial nitric oxide synthase's Ser633 activation site, reversing the adverse effects of low glucose. This protective effect was prevented by L-N G -Nitroarginine methyl ester. Intact human arterioles exposed to low glucose demonstrated marked endothelial dysfunction, which was prevented by either metformin or TEMPOL. Conclusion-Our data suggest that moderate low glucose exposure rapidly impairs NO bioavailability and endothelial function in the human endothelium and that pharmacological AMP kinase activation inhibit this effect in an NO-dependent manner. (Arterioscler Thromb Vasc Biol. 2012;32:712-720.)
Keith Oldham (Medical College of Wisconsin). Full details of the materials used in this study are given in the online-only Data Supplement.
Human adipose arterioles studied were obtained from volunteers without a history of diabetes or coronary artery disease by either subcutaneous gluteal adipose pad biopsy under sterile conditions using local anesthetic (1% lidocaine) or from subcutaneous or visceral fat discarded at the time of abdominal surgery. All samples were obtained in accordance with the policies and procedures of the Medical College of Wisconsin's Institutional Research Board.
Studies were performed primarily under either normal glucose (NG) (5 mmol/L) or LG (2.2 mmol/L) conditions unless otherwise specified. Basal and stimulated NO produced by HUVECs under all conditions were measured using a Model 280 NO Analyzer (Sievers Instruments, Boulder, CO), following an established methodology. 14 Details on cell culture conditions; mitochondrial and total superoxide measurements performed using MitoSox and hydroethidium; mitochondrial membrane potential determined using membrane potential sensitive fluorophores JC-1 and tetramethyl rhodamine methyl ester; Western blots for total endothelial nitric oxide synthase (eNOS), phosphorylated eNOS Ser1177, phosphorylated eNOS Ser633, total AMPK, and phosphorylated AMPK (pAMPK); measurements of human arteriolar endothelial function by videomicroscopy 15 ; and our statistical methods are included in the online-only Data Supplement. A probability value of Ͻ0.05 was considered significant. All data are presented as meanϮSE unless otherwise specified.
Results

Endothelial Cell NO Bioavailability, Mitochondrial Superoxide Production, and Cytosolic Superoxide Production Under LG Conditions
Acute exposure of HUVECs to graded reductions in glucose concentration from 90 to 40 mg/dL resulted in rapid impairment stimulated NO bioavailability with 5 minutes of LG exposure (Figure 1a and 1b) . Impaired NO production began to appear at 80 mg/dL and became significant at 70 mg/dL. Basal levels of NO production were not affected by LG ( Figure I in the online-only Data Supplement). Concomitantly, mitochondrial superoxide significantly increased relative to baseline beginning at 80 mg/dL (Figure 1c ). PEGsuperoxide dismutase completely prevented LG-induced increases in MitoSox fluorescence (Figure 1d ), suggesting that almost all of the MitoSox fluorescence signal originates from mitochondrial superoxide production. Total cellular superoxide levels as measured using hydroethidium did not significantly increase with 60 minutes of exposure to LG (50 mg/dL) ( Figure II in the online-only Data Supplement). However, cellular hydrogen peroxide concentration more than tripled with LG exposure and normalized with concomitant treatment with mito-TEMPOL ( Figure 1e ).
To determine whether free fatty acid supplementation would abrogate LG's stimulation of mitochondrial superoxide production, we measured MitoSox fluorescence under NG (90 mg/dL) and LG (50 mg/dL) conditions with and without supplementation with 1% palmitate and L-carnitine, a mitochondrial antioxidant that can also improve free fatty acid utilization in endothelial cells to under LG conditions, 11 We found that combined treatment of endothelial cells with 1% palmitate and L-carnitine reduced LG-induced mitochondrial superoxide production to normal levels (Figure IIIa in the online-only Data Supplement), However, when examined separately, mitochondrial superoxide production increased under LG conditions with the addition of 1% palmitate, whereas L-carnitine alone returned mitochondrial superoxide levels to those similar to the NG condition ( Figure IIIb in the online-only Data Supplement).
To help delineate the potential mechanisms for reduced NO bioavailability with LG, we measured NO production from HUVECs under NG and LG conditions (30 minutes of exposure). 30 minutes of LG exposure significantly inhibited the conversion of L-arginine to L-citrulline by eNOS ( Figure  1f ). In a subsequent experiments, we supplemented HUVECs with BH 4 , which failed to improve suppressed NO bioavailability of stimulated HUVECs, whereas treatment with 1 mmol/L TEMPOL, with or without BH 4 , significantly improved NO bioavailability ( Figure 1g ).
Effect of LG on Mitochondrial Membrane Potential and Mitochondrial ROS Production: Regulation by NO
To determine whether LG-induced excess mitochondrial ROS production was associated with alterations in mitochondrial membrane potential, we measured mitochondrial membrane potential under both NG and LG conditions. LG induced mitochondrial hyperpolarization relative to NG based on a significant increase in the red:green ratio of JC-1 fluorescence (Figure 2A ; PϽ0.001).
Furthermore, spermine NONOate, an exogenous source of NO, reversed LG-induced mitochondrial hyperpolarization (Pϭ0.97 versus NG alone, Pϭ0.007 versus LG alone), whereas L-N G -Nitroarginine methyl ester (L-NAME) significantly increased mitochondrial membrane potential in the setting of NG (Pϭ0.004 versus NG alone). No significant differences in mitochondrial membrane potential were seen when comparing LG, LGϩL-NAME, or NGϩL-NAME (Pϭnot significant for all post hoc comparisons). Our full results are summarized in Figure 2a . These findings were confirmed using a second mitochondrial membrane potential sensitive probe, tetramethyl rhodamine methyl ester (data not shown). Carbonyl cyanide m-chlorophenyl hydrazone (10 mol/L) significantly reduced mitochondrial membrane potential relative to both NG and LG condition using JC-1, confirming the ability of JC-1 to measure changes in membrane potential (data not shown).
To confirm that losses of NO production lead to increased mitochondrial ROS production, we performed additional experiments under NG and LG conditions with and without L-NAME (1 mmol/L) or spermine NONOate (10 mol/L) and measured mitochondrial ROS production ( Figure 2b ). L-NAME increased mitochondrial ROS production under NG conditions to the level of LG, whereas NONOate prevented LG-induced mitochondrial ROS production.
Effect of LG on AMPK Activity Relative to eNOS Phosphorylation at Serine 1177 and Serine 633 Activation Sites
To determine the time course of AMP activation following LG exposure, we measured pAMPK levels between 0 and 120 minutes following exposure to LG. As demonstrated in Figure 3a and 3b, the ratio of pAMPK to total AMPK increased 75% from time 0 to 15 to 30 minutes following
LG exposure. Although pAMPK/total AMPK remained modestly elevated at 45 to 60 minutes of LG exposure compared with time zero (32% increase over baseline), the ratio was significantly lower than at 15 to 30 minutes.
In contrast to AMPK, the eNOS serine 1177 activation site was rapidly dephosphorylated (within 5 minutes of LG exposure), and this level inhibition was maintained out to 120 minutes of LG exposure (Figure 3c and 3d ).
Effect of Pharmacological AMPK Activation on eNOS Phosphorylation at Activation Sites, Mitochondrial Superoxide Production, and NO Bioavailability
We exposed HUVECs under NG and LG condition to metformin (10 mol/L) for 1 hour and measured eNOS phosphorylation at the Ser1177 and Ser633 activation sites. Metformin had no significant effect on LG-induced dephos- LG) exposure on human umbilical vein endothelial cell nitric oxide (NO) and mitochondrial superoxide production. a, Impairment of vascular endothelial growth factor (VEGF)-stimulated NO production relative to basal NO production appeared to begin at 80 mg/dL (nϭ8, PϽ0.001 overall), with significant decreases in net NO production at concentrations Յ70 mg/dL (*PϽ0.001 vs 90 mg/dL). b, Net NO production following VEGF stimulation was significantly suppressed at 5, 30, and 60 minutes following exposure to LG (nϭ6, PϽ0.001 overall, *PϽ0.05 at all time points relative to normal glucose [NG]). c, Mitochondrial superoxide production as a percentage of control glucose concentration (90 mg/dL) was significantly increased at glucose concentrations of Յ80 mg/dL (nϭ8, PϽ0.001 overall, *PϽ0.05 vs 90 mg/dL at all time points). d, MitoSox signal under LG conditions was completed eliminated in the presence of either PEGsuperoxide dismutase (nϭ8, PϽ0.001 overall, PϽ0.05 for LG vs all other conditions). e, LG induced a significant increase in cellular hydrogen peroxide levels as measured by 2=7=-dichlorofluorescein (DCF) fluorescence intensity. This increase was completely suppressed by mitochondrial targeted antioxidant therapy with mito-TEMPOL (1 mmol/L) (*Pϭ0.01 overall, PϽ0.05 for LG vs all other exposure states). f, 30 minutes of LG exposure significantly inhibited NO production, as measured by the conversion of L-arginine to L-citruilline (nϭ12, 731Ϯ273 vs 206Ϯ62 fmol citrulline/mg protein per minute, Pϭ0.026). g, The addition of BH 4 (100 mol/L) had no effect on LG-induced inhibition of stimulated NO production. TEMPOL (1 mmol/L) significantly reversed LG-induced inhibition of stimulated NO production with or with the concomitant presence of BH 4 (nϭ5-9, PϽ0.001 overall, PϽ0.02 for LG vs all other conditions except LGϩBH 4 ). A.U. indicates arbitrary units. phorylation at Ser1177 (Figure 3e and 3f). However, metformin significantly increased eNOS phosphorylation at Ser633 under both LG and NG conditions, whereas LG alone had no effect on Ser633 phosphorylation (Figure 3g and 3h).
Incubation with either metformin or 5-aminoimidazole-4carboxamide-1-B-D-ribofuranoside (AICAR), both pharmacological activators of AMPK, for 1 hour blocked mitochondrial superoxide production during LG ( Figure 4a ). This was accompanied by an increase in NO bioavailability during AICAR and metformin exposure ( Figure 4b ). Reductions in mitochondrial superoxide produced by AICAR or metformin treatment were inhibited by concomitant exposure to L-NAME ( Figure IV 
Effect of Acute LG Exposure on Endothelial Function
We isolated subcutaneous or mesenteric adipose arterioles from human volunteers without underlying atherosclerotic disease or diabetes for analysis of endothelium-dependent vasoreactivity under NG and LG conditions. Glucose concentration had no effect on the resting diameters of arterioles (100Ϯ13 versus 94Ϯ15 nmol/L for NG and LG, respectively; Pϭ0.09) As seen in Figure 5a , exposure to LG significantly blunted endothelium-dependent vasodilation to acetylcholine.
LG with concomitant metformin or PEG-superoxide dismutase exposure effectively inhibited the adverse effects of LG on endothelium-dependent vasodilation. No significant differences in endothelial function were found between NG,
LGϩmetformin, and LGϩsuperoxide dismutase conditions. There were no significant differences in vasoreactivity to papaverine among exposure conditions ( Figure 5a ), and there was no difference in vasodilation to NONOate under LG compared with NG ( Figure 5b ). Using L-glucose (3 mmol/L) to equalize the osmolarity of the buffer had no effect on LG (2 mmol/L) impairment of arteriolar endothelial function ( Figure V in the online-only Data Supplement).
Discussion
The present investigation has identified 3 novel findings. First, acute exposure of endothelial cells to LG concentrations in a clinically relevant range (40 -80 mg/dL) induced a rapid reduction in NO bioavailability at least in part through dephosphorylation of at the serine 1177 site. Second, the loss of NO bioavailability was mechanistically linked to concomitant increases in mitochondria specific superoxide production, likely through mitochondrial hyperpolarization. Third, although native AMPK activation was not sufficient to maintain levels of activated eNOS and inhibit excessive mitochondrial superoxide production, pharmacological AMPK activation inhibited excessive mitochondrial oxidative stress through improved NO bioavailability that may involve phosphorylation at eNOS's Ser633 activation site. Importantly, we demonstrated that our findings have relevance to human vascular endothelial function by showing that acute LG exposure profoundly impaired endothelial function in intact human adipose arterioles, whereas treatment with metformin or a superoxide scavenger designed to pass through membranes inhibited the adverse effects of LG. Taken together, these data suggest a new mechanism of inducing vascular mitochondrial oxidative stress and endothelial dysfunction, namely, brief hypoglycemia, typical of the clinical situation involving tight glycemic regulation.
The consequences of tight glycemic control include intermittent hypoglycemia in the range that we identify as capable of increasing mitochondrial oxidative stress and endothelial dysfunction. There have been few prior investigations of the effect of LG on endothelial function, and prior work in this area has been conflicting. Exposure of porcine aortic endothelial cells to 2-deoxyglucose in a glucose-free environment inhibits bradykinin-stimulated production of prostacyclin and possibly NO as well. 16 In a study of rabbit aortas, inhibition of glycolysis with either 2-deoxyglucose or iodoacetate in buffer containing 16.6 mmol/L glucose failed to alter endothelium-dependent vasodilation to acetylcholine. 17 A third study assessed the effect of moderate and severe insulininduced hypoglycemia on cerebral blood flow in goats, finding an NO-dependent increase in cerebral blood flow under hypoglycemic conditions. 18 These studies are significantly heterogeneous with respect to their study designs, including significant differences in the species studied, vascular beds tested, and methodologies used to induce LG states. The porcine and rabbit studies used inhibitors of glycolysis enzymes to mimic the effects of glucose deprivation, limiting their generalizability to physiologically relevant LG states. Our findings significantly expand our knowledge †Pϭ0.004 for NG vs NGϩL-NAME). b, L-NAME increased mitochondrial ROS production under NG (90 mg/dL D-glucose) to the level seen under LG conditions (40 mg/dL D-glucoseϩ50 mg/dL L-glucose). Spermine NONOate exposure prevented LG-induced increases in mitochondrial ROS production. No increase in mitochondrial ROS production was seen with the addition of L-NAME under LG conditions (PϽ0.001 overall; *PϽ0.005 for NGϩL-NAME vs NG and LGϩNONOate; †PϽ0.008 for LG vs NG, NGϩNONOate, and LGϩNONOate).
base on the effects of LG on human vascular endothelial function through the use of human tissues and clinically relevant concentrations of glucose.
Our data demonstrated that LG exposure rapidly inhibits NO bioavailablity at least in part through reducing the level of Ser1177 phosphorylated eNOS. Mechanistically, the loss of NO bioavailability may also relate to our observed increase total cellular oxidative stress observed in this study by an increase in H 2 O 2 under LG conditions. We were unable to show evidence of excessive total superoxide levels under LG conditions. Although we cannot exclude an effect on total superoxide concentrations for longer exposure periods, our data suggest that a 60-minute period of LG exposure does not induce excessive total superoxide levels. Our data are also consistent with prior work demonstrating that glucose deprivation inhibits the phosphatydylinositol 3-kinase/Akt signaling pathway intrinsic to the activation of eNOS. 19 Our data significantly expand on this finding by (1) extending the prior study's findings to clearly demonstrate an effect on eNOS and (2) demonstrating the potential clinical relevance of inhibition of this pathway at physiological levels of LG. Further work to delineate the mechanisms of eNOS inactivation by LG is necessary to determine potential targets for interventions. NO is a key regulator of the mitochondrial electron transport chain (ETC), the major source of mitochondrial superoxide. 20 NO modulates ETC activity through inhibition of complexes I and IV. 21, 22 Under normal homeostatic conditions, relatively high levels of NO in endothelial cells significantly inhibit ETC activity. 23 Our data suggest that LG-induced losses of bioavailable NO remove homeostatic restrictions on mitochondrial ETC flux, leading to mitochondrial hyperpolarization and superoxide production. Mitochondrial hyperpolarization, as induced in our study by LG, is well known to be mechanistically related to increased mitochondrial ROS production. 10,24 -26 Our novel findings in the setting of LG are consistent with prior work demonstrating that the amount of glucose oxidation via the Krebs cycle, near dormant under NG conditions in endothelial cells, is significantly increased with LG exposure. 27 Data from the neurological literature demonstrate hypoglycemia shifts mitochon-dria from state 3 to state 4 respiration in central neurons, an alteration well known for increasing mitochondrial superoxide production. 28 Subsequent work also shows neuronal hypoglycemia induces marked increases in both mitochondrial superoxide and hydrogen peroxide production. 29, 30 Further work using inhibitors of the mitochondrial ETC and measurements of specific activity levels of components of the ETC will be necessary to determine the exact ETC sources of mitochondrial ROS under LG conditions.
We found that LG exposure enhances endothelial cell H 2 O 2 content with a corresponding increase in mitochondrial superoxide content. Increases in ROS production are linked to increased oxidative damage, reduced NO bioavailability, and endothelial dysfunction. 31 In the context of our findings, the biological role of increased mitochondrial superoxide under LG conditions likely includes both the adverse sequelae of increased oxidative damage, as well as modulation of impor- tant pathological cell signaling cascades. Mitochondrial superoxide can reduce NO bioavailability by rapidly reacting locally with NO to form peroxynitrite. Peroxynitrite formation reduces NO bioavailability and can itself damage the ETC, antioxidant defenses, and mitochondrial proteins and nucleic acids. 32 Our data are also consistent with the emerging concept of that mitochondrial ROS, particularly hydrogen peroxide (H 2 O 2 ), are central regulators of homeostatic and pathological cell signaling in endothelial cells. 33, 34 Although superoxide can escape from mitochondria in modest quantities, the concentrations of more stable H 2 O 2 (produced by rapid dismutation of superoxide to H 2 O 2 in both the mitochondrial matrix and intermembrane space) far exceed that of superoxide in mitochondria. 35 H 2 O 2 can easily pass through mitochondrial membranes. 36 H 2 O 2 has previously been reported to activate AMPK via calcium/calmodulin-dependent protein kinase kinase ␤. 37 Prior work also establishes the ability of NO to reduce mitochondrial H 2 O 2 production via suppression superoxide production from the mitochondrial ETC. 38 Our data are entirely consistent with this previously established regulatory nexus of H 2 O 2 , AMPK, and NO. We have importantly extended these findings by showing exposure to LG at clinically relevant concentrations and exposure times triggers this regulatory pathway, beginning with a loss of NO bioavailability, a concomitant increase in mitochondrial H 2 O 2 production, and an increase in AMPK activity.
Interestingly, we found that treatment with either metformin or AICAR, known pharmacological activators of AMPK through activation of tumor suppressor product LKB1, reversed the loss of NO bioavailability and inhibited excessive mitochondrial oxidative stress. Further, metformin reversed endothelial dysfunction in intact human arterioles acutely exposed to moderate LG concentrations. These data are consistent with prior work demonstrating AMPK activation of eNOS and NO suppression of mitochondrial ETC activity. 12, 23 Inhibition of eNOS using L-NAME prevented the effects of metformin and AICAR, further suggesting that the ameliorative effects of pharmacological AMPK activation are mechanistically linked to increased NO bioavailability.
One potential paradox in our findings is that increased pAMPK with LG exposure alone failed to increase NO levels even out to 2 hours of LG exposure. Based on prior work and our data in Figure 3 , we suspect that this initially puzzling finding relates to differences in the isoform of AMPK activated by metformin and AICAR (AMPK␣2 via activation of LKB1) 39 versus the isoform activated by H 2 O 2 (AMPK␣1 via activation of calcium/calmodulin-dependent protein kinase kinase ␤) 37 and the relative importance of each isoform in regulating eNOS activity. Although AMPK␣1 is more abundant in endothelial cells, AMPK␣2 activity appears to be of significantly greater importance in eNOS regulation. In endothelial cells, pAMPK␣2 plays a key role in activating eNOS and increasing NO bioavailability, whereas there is minimal to no role for AMPK␣1 in eNOS regulation. 12 Furthermore, these data would suggest that pharmacological AMPK␣2 activation may have a protective effect against LG-induced endothelial dysfunction. Future work is clearly indicated to confirm this attractive hypothesis. Figure 6 provides a graphical synthesis of our findings with previously reported work in this area.
Our findings with respect to fatty acid and L-carnitine suggest mechanistically that free fatty acid utilization in vivo would not be sufficient to suppress LG-induced NO suppression and excessive mitochondrial superoxide pro- LGϩPEG-SOD at the indicated concentrations of acetylcholine. b, LG did not alter endothelium-independent responses to exogenous nitric oxide (NO) (NONOate, nϭ3. Pϭ0.20 for interaction between dose and exposure condition). Ach indicates acetylcholine; PAP, papaverine. LG exposure leads to rapid inhibition of endothelial nitric oxide synthase (eNOS) and a reduction in bioavailable nitric oxide (NO). This leads to a subsequent increase in mitochondrial electron transport chain activity, mitochondrial membrane hyperpolarization, and increased mitochondrial superoxide production. Increased mitochondrial superoxide production can further reduce NO bioavailability and leads to increased cellular hydrogen peroxide levels that activate AMPK isoform ␣1 through a calcium/calmodulindependent protein kinase kinase ␤ (CaMKK␤)-dependent pathway.
LG-induced losses of NO bioavailability could be prevented/reversed by treatment with AMPK␣2 activating agents acting through an LKB1-dependent activation pathway. duction, particularly in diabetic patients who have significant impairment in free fatty acid utilization and reduced basal plasma and tissue carnitine levels. 40, 41 Interestingly, our data does suggest that pharmacological supplementation with L-carnitine may be able to inhibit the adverse effects of LG on mitochondrial superoxide production and perhaps improve endothelial dysfunction. L-Carnitine plays a key role in both transporting and intracellular handling of fatty acids, 42 and L-carnitine supplementation has been shown to improve NO bioavailability and blunt free fatty acid-induced endothelial dysfunction. 43 The mechanism of the vascular benefits of L-carnitine remains unclear, and further work is necessary to delineate the efficacy and mechanism of action of L-carnitine in the setting of LG.
Our data have limitations. First, HUVECs may not be representative of other vascular endothelial cells. However, we tested arteriolar endothelial function of intact human vessels and verified that LG induces a state of endothelial dysfunction reversible with metformin and antioxidant therapy, suggesting our findings have physiological relevance to human arteriolar endothelial function. Second, the mechanism of eNOS inactivation beyond dephosphorylation at Ser1177 under LG conditions remains unknown and will need to be elucidated in future work. Although our data demonstrate eNOS phosphorylation at the 1177 serine site occurs on exposure to LG conditions in a time-dependent manner, experiments with eNOS 1177 mutants would reinforce our findings. Third, we did not specifically measure the contributions of AMPK␣1 and AMPK␣2. Future work will be necessary to verify the AMPK isoform specific effects that we suspect explain the differential effects of physiological H 2 O 2 based AMPK activation and pharmacological AMPK activation. Finally, metformin's ameloriative effects may also include augmentation of endothelial cell glucose uptake through activated AMPK directed increases in GLUT1 activity or blockade of mitochondrial ETC complex I. 44, 45 Both mechanisms could also blunt mitochondrial superoxide production. Further investigation will be necessary to determine the contribution of this metformin effect to our findings. Balanced against these limitations is the novelty of our findings, our evidence of physiological relevance in human arterioles, and the potential clinical implications of these data regarding the cardiovascular dangers of hypoglycemia.
Conclusions and Clinical Implications
Acute exposure to clinically relevant levels of LG rapidly induces a state of endothelial dysfunction, characterized by reduced NO bioavailability, mitochondrial hyperpolarization, increased mitochondrial ROS production, and vasomotor dysfunction. Physiological AMPK activity modestly increases with LG exposure likely secondary to increased mitochondria-derived H 2 O 2 levels. Pharmacological AMPK activation, which relies on a different AMPK isoform than that activated by physiological H 2 O 2 , reverses LG-induced endothelial dysfunction at least in part through inhibiting excessive mitochondrial superoxide production in an eNOSdependent manner.
Hypoglycemic symptoms often do not occur until systemic levels drop below 55 mg/dL. 46 Our data support the biological plausibility that acute hypoglycemia may result in the acute development or worsening of endothelial dysfunction, triggering cardiovascular events. Further, our data suggest the potential for pharmacological AMPK activation, and perhaps L-carnitine, to inhibit these effects. 8 Further work is needed to determine whether in vivo hypoglycemia, similar to hyperglycemia, is also a significant risk factor for endothelial dysfunction. Such confirmation would help explain the observed detrimental effect of tight glycemic control on cardiovascular events and have important ramifications in the treatment strategies for glucose control in diabetes.
